Skip to content

Naturopathic-pharmacological Consultation in Hematology

Naturopathic-pharmacological Consultation on the Use of Dietary Supplements in Patients With Hematological Diseases

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05982262
Enrollment
100
Registered
2023-08-08
Start date
2023-06-15
Completion date
2028-06-30
Last updated
2024-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Diseases

Keywords

Dietary supplements, Herbal supplements, Hematology, Safety, Consultation, Naturopath, Clinical pharmacist

Brief summary

The goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions. The main question it aims to answer is whether such consultation can improve the safety of dietary and herbal supplements' use among these patients. Participants will be asked to answer basic questions and fill-out questionnaire before and after meeting the consultation team. Some patients will be prescribed dietary and herbal supplements that may help relief some of the symptoms they describe, in a safe way and without interacting with the drugs they are taking.

Interventions

OTHERNaturopathic-pharmacological consultation

The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.

Sponsors

Bnai Zion Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Followed up for a hematological condition 2. Ability to fill simple questionnaires in Hebrew, Russian or Arabic 3. Indication for consultation: 1. Patient's request to expand knowledge about the use of DHS 2. Patient using DHS 3. Patient's desire to start using DHS 4. Patient that is interested in hearing about the use of DHS for his/her health condition 5. Medical or nursing team's recommendation to take DHS for medical treatment or to improve compliance with conventional treatment.

Exclusion criteria

None

Design outcomes

Primary

MeasureTime frameDescription
Safety of the use of DHS in patients with a hematological disease through naturopathic counselingFrom enrollment to the end of intervention, up to 1 yearNumber of potential interactions with moderate to major level of significance prevented by the naturopathic consultation in each patient, as well as the incidence of DHS-related safety events. The Naranjo and modified Food and Drug Administration algorithm will be used to assess the causality of such events with the specific dietary supplements, and only side effects at least possibly caused by the DHS according to these scales will be considered.

Secondary

MeasureTime frameDescription
Efficacy of prescribed dietary and herbal supplements (DHS)From enrollment to the end of intervention, up to 1 yearMeasure Yourself Concerns and Wellbeing (MYCAW) questionnaire: requires participants to nominate one or two concerns and, using a seven-point scale from 0 (worse outcome) to 6 (best outcome), to score these concerns and their general feeling of wellbeing.
Patient-physician communication around the use of DHSFrom enrollment to the end of intervention, up to 1 yearAsking the patient whether the topic has been brought up with the treating hematologist and checking the documentation of the use of DHS in the medical charts
Patient satisfactionFrom enrollment to the end of intervention, up to 1 yearDirect question asked after each meeting ranking in a 1-5 Likert scale the satisfaction of the patient from the consultation: from 1 (not satisfied at all) to 5 (maximal satisfaction)
Compliance with hematological treatmentFrom enrollment to the end of intervention, up to 1 yearRelative dose intensity (RDI) of the prescribed hematological drugs both before and after intervention: The term of dose intensity (DI) is used to define the drug dose delivered per time unit and is expressed as mg/m2 per week. A delay in the sequence of treatment cycles decreases the DI in the same proportion as a reduction of dose. Average relative DI corresponds to the mean DI of combined agents and is expressed as a fraction of a similar combination selected as a standard
Qualitative evaluation of the staff and patients from naturopathic-pharmacological counselingFrom enrollment to the end of intervention, up to 1 yearSemi-structured in-depth interviews will be conducted with patients who are interested in participating in the qualitative arm (10-15 patients) and the staff members involved (medical staff, nursing staff, naturopath, clinical pharmacist). The goal is to describe the process of building the naturopathic-pharmacological consultation and evaluate the satisfaction of the staff and patients

Countries

Israel

Contacts

Primary ContactDana Weizer
dana.weizer@b-zion.org.il972543295952

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026